Bioindicators Associated With Sarcopenia Before and After Intensive Lifestyle Intervention
- Disease/Condition
- Sarcopenia
- Drug/Device/Intervention
- 3-month intensive intervention
- Study type
- Interventional
- Intervention type
- combination product
- Primary sponsor
- Lijun Yang
- Funder
- Suzhou Municipal Hospital
- Location
- Suzhou, China
- Phase
- Phase 4
- Start date
- Mar 01, 2022
- End date
- Aug 02, 2022
- Enrollment
- 99 participants
AMMI(appendicular muscle mass index)
The goal of this clinical trial is to explore whether the bioindicators of body composition,
 nutrition-related indicators (lymphocytes, albumin), lipids, and thyroid hormones are
 associated with sarcopenia and the changes in these indicators after an intensive lifestyle
 intervention. The main questions it aims to answer are:
 
 - whether the bioindicators such as lymphocytes, albumin, lipids, thyroid hormones, fat
 mass, fat-free mass, and basal metabolic mass are associated with the development of
 sarcopenia.
 
 - the changes of these bioindicators that occur in older adults after going through an
 intensive intervention.
 
 Participants will receive a 3-month intensive intervention consisting of an intensive
 nutritional intervention and an individually designed exercise intervention. Nutritional and
 exercise prescriptions are co-designed through a nutritionist and rehabilitation physician.
 
 Researchers will compare bioindicators in the sarcopenia group before and after intensive
 lifestyle intervention to determine the association with sarcopenia.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06128577
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT06128577 through Pure Global AI's free database. This Phase 4 trial is sponsored by Lijun Yang and is currently Completed. The study focuses on Sarcopenia. Target enrollment is 99 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.